dimethylglyoxime and Alzheimer-Disease

dimethylglyoxime has been researched along with Alzheimer-Disease* in 1 studies

Other Studies

1 other study(ies) available for dimethylglyoxime and Alzheimer-Disease

Article	Year
The nickel-chelator dimethylglyoxime inhibits human amyloid beta peptide in vitro aggregation. Scientific reports, 2021, 03-23, Volume: 11, Issue:1 One of the hallmarks of the most common neurodegenerative disease, Alzheimer's disease (AD), is the extracellular deposition and aggregation of Amyloid Beta (Aβ)-peptides in the brain. Previous studies have shown that select metal ions, most specifically copper (Cu) and zinc (Zn) ions, have a synergistic effect on the aggregation of Aβ-peptides. In the present study, inductively coupled plasma mass spectrometry (ICP-MS) was used to determine the metal content of a commercial recombinant human Aβ Topics: Alzheimer Disease; Amyloid beta-Peptides; Chelating Agents; Copper; Dose-Response Relationship, Drug; Drug Discovery; Humans; Metals; Nickel; Oximes; Protein Aggregates; Protein Aggregation, Pathological; Zinc	2021

Article

Year

The nickel-chelator dimethylglyoxime inhibits human amyloid beta peptide in vitro aggregation.

Scientific reports, 2021, 03-23, Volume: 11, Issue:1

One of the hallmarks of the most common neurodegenerative disease, Alzheimer's disease (AD), is the extracellular deposition and aggregation of Amyloid Beta (Aβ)-peptides in the brain. Previous studies have shown that select metal ions, most specifically copper (Cu) and zinc (Zn) ions, have a synergistic effect on the aggregation of Aβ-peptides. In the present study, inductively coupled plasma mass spectrometry (ICP-MS) was used to determine the metal content of a commercial recombinant human Aβ

Topics: Alzheimer Disease; Amyloid beta-Peptides; Chelating Agents; Copper; Dose-Response Relationship, Drug; Drug Discovery; Humans; Metals; Nickel; Oximes; Protein Aggregates; Protein Aggregation, Pathological; Zinc

2021